131 related articles for article (PubMed ID: 4439501)
101. BCG immunotherapy in patients with malignant melanoma.
Karakousis CP; Douglass HO; Yeracaris PM; Holyoke ED
Arch Surg; 1976 Jun; 111(6):716-8. PubMed ID: 776125
[TBL] [Abstract][Full Text] [Related]
102. The rationale of immunostimulation procedures in the therapeutic approach to malignant melanoma of the skin.
Ikonopisov RL
Tumori; 1972; 58(2):121-7. PubMed ID: 4560893
[No Abstract] [Full Text] [Related]
103. Intravenous administration of BCG in advanced melanoma patients.
Orefice S; Cascinelli N; Vaglini M; Veronesi U
Tumori; 1978; 64(4):437-43. PubMed ID: 684866
[TBL] [Abstract][Full Text] [Related]
104. Anthropometry in the immunotherapy of cutaneous and ocular melanomas.
Săftescu S; Munteanu M; Popovici D; Dragomir R; Dărăbuș MD; Negru AG; Negru ȘM
Rom J Ophthalmol; 2020; 64(2):190-194. PubMed ID: 32685786
[TBL] [Abstract][Full Text] [Related]
105. The significance of conversion of skin reactivity to efficacy of bacillus Calmette-Guérin (BCG) vaccinations given immediately after radical surgery in stage II melanoma patients.
Cascinelli N; Rümke P; MacKie R; Morabito A; Bufalino R
Cancer Immunol Immunother; 1989; 28(4):282-6. PubMed ID: 2702680
[TBL] [Abstract][Full Text] [Related]
106. Immunotherapy of melanoma with intralesional BCG.
Bornstein RS; Mastrangelo MJ; Sulit H; Chee D; Yarbro JW; Prehn LM; Prehn RT
Natl Cancer Inst Monogr; 1973 Dec; 39():213-20. PubMed ID: 4595320
[No Abstract] [Full Text] [Related]
107. Experience with BCG adjuvant immunotherapy in stage II malignant melanoma.
Deutschmann KE; Peter HH; Schultheis W; Deicher H
Tumori; 1977; 63(3):303-7. PubMed ID: 898298
[TBL] [Abstract][Full Text] [Related]
108. [Cancer immunotherapy in dermatological view (author's transl)].
Lübbe D; Gstöttner R
Arch Geschwulstforsch; 1980; 50(2):182-5. PubMed ID: 7436703
[TBL] [Abstract][Full Text] [Related]
109. [Clinical administration of BCG-immunotherapy in malignant melanoma (author's transl)].
Wätzig V; Knopf B
Arch Geschwulstforsch; 1979; 49(2):140-5. PubMed ID: 475550
[TBL] [Abstract][Full Text] [Related]
110. BCG stimulation of immune responsiveness in patients with malignant melanoma. Preliminary report.
Gutterman J; Mavligit G; McBride C; Frei E; Hersh EM
Cancer; 1973 Aug; 32(2):321-7. PubMed ID: 4722915
[No Abstract] [Full Text] [Related]
111. [Intranodular treatment with BCG of cutaneous and subcutaneous metastases of malignant melanoma (author's transl)].
Balzarini GP; Cascinelli N; Fontana V; Veronesi U
Tumori; 1974; 60(4):345-52. PubMed ID: 4439501
[No Abstract] [Full Text] [Related]
112. Immunology and cutaneous malignant melanoma.
Sober AJ
Int J Dermatol; 1976; 15(1):1-18. PubMed ID: 1107238
[No Abstract] [Full Text] [Related]
113. Adjuvant therapy of cutaneous malignant melanoma: a critical review.
Koh HK; Sober AJ; Harmon DC; Lew RA; Carey RW
Med Pediatr Oncol; 1985; 13(5):244-60. PubMed ID: 3897817
[TBL] [Abstract][Full Text] [Related]
114.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
115.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
116.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
117.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
118.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
119.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
120.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
